Summary & Overview
CPT 55860: Perineal Access for Prostate Brachytherapy
CPT code 55860 denotes a surgical perineal incision to expose the prostate and enable insertion of radioactive material for treatment of prostate cancer. This code captures the access portion of prostate brachytherapy when one clinician creates the surgical approach and another typically performs the radioactive implant. Nationally, the code matters because it distinguishes the access procedure from the implant itself for billing, coverage determinations, and quality measurement in prostate cancer care pathways.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for CPT code 55860, benchmarking considerations used by major commercial and federal payers, and the typical sites of service where the procedure is performed. The publication outlines coding relationships relevant to brachytherapy workflows, summarizes common modifier usage reported by payers where available, and highlights operational points for claims submission and unitization of services.
This summary is written for a national audience and is intended to clarify what CPT code 55860 represents, why the distinction between access and implantation is important for billing and care coordination, and what topics a reader can expect in the full publication, including reimbursement benchmarks, payer policy trends, and clinical service-line implications.
Billing Code Overview
CPT code 55860 describes a surgical perineal incision performed to expose the prostate and permit insertion of radioactive material, typically delivered by a separate provider, for treatment of malignant prostate cancer. This procedure is a surgical access procedure used in the delivery of brachytherapy for prostate malignancy.
-
Service type: Surgical access for brachytherapy
-
Typical site of service: Operating room or ambulatory surgery center
Clinical & Coding Specifications
Clinical Context
A typical patient is a man diagnosed with localized or locally advanced prostate cancer who is scheduled for perineal implantation of radioactive seeds (brachytherapy). The patient is generally a man in his 50s–80s with biopsy-proven adenocarcinoma of the prostate, often after staging with prostate-specific antigen (PSA) testing, multiparametric MRI, and transrectal ultrasound. The surgical team includes a urologist who performs the perineal incision and prostate exposure and a radiation oncologist or brachytherapy specialist who implants the radioactive seeds during the same operative session or immediately after exposure. The procedure is performed in an ambulatory surgery center or hospital operating room under general or regional anesthesia. Preoperative preparation includes informed consent, review of anticoagulation, bowel prep when applicable, and prophylactic antibiotics. Intraoperative workflow: patient positioned in lithotomy, sterile prep, perineal incision is made, tissues are dissected to expose the prostate, transrectal ultrasound or fluoroscopic guidance is used for needle guidance, and the brachytherapy specialist places seeds through hollow needles into planned prostate locations. Hemostasis is secured and incision closed. Postoperative care includes recovery room monitoring, instructions on wound care, activity restrictions, pain control, and follow-up with radiation oncology for dosimetry review and with urology for wound and urinary function assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period |